Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LEGNNASDAQ:SRPTNASDAQ:TGTXNASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLEGNLegend Biotech$32.01-2.6%$36.22$30.17▼$60.87$5.88B0.191.21 million shs1.46 million shsSRPTSarepta Therapeutics$54.43-7.1%$98.19$54.30▼$173.25$5.28B0.791.32 million shs4.58 million shsTGTXTG Therapeutics$37.35-5.1%$35.15$12.93▼$43.32$5.87B2.133.08 million shs3.13 million shsTVTXTravere Therapeutics$14.99-9.5%$20.59$5.12▼$25.29$1.33B0.841.50 million shs2.86 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLEGNLegend Biotech-1.08%-7.09%-3.24%-8.11%-41.68%SRPTSarepta Therapeutics-6.18%-18.38%-43.02%-53.59%-53.82%TGTXTG Therapeutics-1.21%-2.14%+10.44%+30.92%+171.87%TVTXTravere Therapeutics-7.69%-18.70%-15.94%-12.20%+137.25%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLEGNLegend Biotech2.489 of 5 stars3.53.00.00.02.91.70.6SRPTSarepta Therapeutics4.7611 of 5 stars4.43.00.04.23.02.51.9TGTXTG Therapeutics2.8066 of 5 stars1.40.00.03.53.42.51.9TVTXTravere Therapeutics2.4772 of 5 stars4.51.00.00.02.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLEGNLegend Biotech 2.92Moderate Buy$79.00146.80% UpsideSRPTSarepta Therapeutics 2.83Moderate Buy$163.18199.80% UpsideTGTXTG Therapeutics 2.83Moderate Buy$40.678.88% UpsideTVTXTravere Therapeutics 2.93Moderate Buy$31.46109.88% UpsideCurrent Analyst Ratings BreakdownLatest TVTX, LEGN, TGTX, and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2025SRPTSarepta TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$202.00 ➝ $183.004/3/2025TVTXTravere TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight4/2/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Neutral$75.00 ➝ $75.004/1/2025TVTXTravere TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $31.003/31/2025SRPTSarepta TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$161.00 ➝ $87.003/20/2025SRPTSarepta TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$105.00 ➝ $80.003/19/2025SRPTSarepta TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$124.00 ➝ $99.003/19/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell ➝ Sell$75.00 ➝ $75.003/18/2025SRPTSarepta TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$202.00 ➝ $202.003/18/2025SRPTSarepta TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$163.00 ➝ $163.003/17/2025LEGNLegend BiotechMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$82.00 ➝ $80.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLEGNLegend Biotech$627.24M9.37N/AN/A$6.88 per share4.65SRPTSarepta Therapeutics$1.90B2.78N/AN/A$9.19 per share5.92TGTXTG Therapeutics$329.00M17.83$0.11 per share353.90$1.06 per share35.24TVTXTravere Therapeutics$233.18M5.70N/AN/A$2.67 per share5.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLEGNLegend Biotech-$518.25M-$0.48N/AN/AN/A-66.92%-29.69%-19.45%5/12/2025 (Estimated)SRPTSarepta Therapeutics-$535.98M$2.2843.544.98N/A7.43%11.00%3.35%4/29/2025 (Estimated)TGTXTG Therapeutics$12.67M$0.14N/A37.35N/A-5.42%-8.32%-3.40%4/29/2025 (Estimated)TVTXTravere Therapeutics-$111.40M-$4.10N/AN/AN/A-137.90%-1,636.87%-55.95%5/5/2025 (Estimated)Latest TVTX, LEGN, TGTX, and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/11/2025Q4 2024LEGNLegend Biotech-$0.39$0.07+$0.46$0.07$179.00 million$186.50 million3/3/2025Q4 2024TGTXTG Therapeutics$0.08$0.15+$0.07$0.15$100.67 million$108.19 million2/20/2025Q4 2024TVTXTravere Therapeutics-$0.58-$0.73-$0.15-$0.73$72.38 million$74.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLEGNLegend BiotechN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLEGNLegend Biotech0.274.984.90SRPTSarepta Therapeutics0.933.843.03TGTXTG Therapeutics1.274.593.91TVTXTravere Therapeutics24.961.711.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLEGNLegend Biotech70.89%SRPTSarepta Therapeutics86.68%TGTXTG Therapeutics58.58%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipLEGNLegend Biotech0.02%SRPTSarepta Therapeutics7.70%TGTXTG Therapeutics10.50%TVTXTravere Therapeutics3.75%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLEGNLegend Biotech1,070183.65 million182.60 millionOptionableSRPTSarepta Therapeutics84097.03 million88.17 millionOptionableTGTXTG Therapeutics290157.07 million139.32 millionOptionableTVTXTravere Therapeutics46088.74 million75.12 millionOptionableTVTX, LEGN, TGTX, and SRPT HeadlinesRecent News About These CompaniesNovartis Has A Slight Edge On Travere — Why Analysts Aren't WorriedApril 3 at 7:30 PM | msn.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Stock Position Lessened by Pictet Asset Management Holding SAApril 3 at 4:18 AM | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Bank of America Analyst SaysApril 3 at 4:01 AM | americanbankingnews.comThe Analyst Verdict: Travere Therapeutics In The Eyes Of 7 ExpertsApril 3 at 3:00 AM | benzinga.comBank of America Raises Travere Therapeutics (NASDAQ:TVTX) Price Target to $31.00April 2 at 8:44 AM | marketbeat.comKnott David M Jr Has $3.97 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)April 2 at 7:07 AM | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Stock Price Down 8% - Here's What HappenedApril 1 at 2:00 PM | marketbeat.comTravere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025March 31, 2025 | finance.yahoo.comTravere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025March 31, 2025 | businesswire.comTwo S&P 500 Giants And Biotech Play Lead Five Stocks To Watch As Market StrugglesMarch 29, 2025 | investors.comPrudential Financial Inc. Acquires 365,200 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)March 29, 2025 | marketbeat.comEntryPoint Capital LLC Acquires New Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)March 28, 2025 | marketbeat.comSwiss National Bank Has $2.65 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)March 28, 2025 | marketbeat.comIs Market Volatility Good For Small-Cap Stocks?March 27, 2025 | uk.finance.yahoo.comIs Travere Therapeutics, Inc. (NASDAQ:TVTX) the Best Small Cap Stock to Buy Before They Explode?March 27, 2025 | msn.comFox Run Management L.L.C. Purchases Shares of 25,708 Travere Therapeutics, Inc. (NASDAQ:TVTX)March 26, 2025 | marketbeat.comEmerald Advisers LLC Acquires 165,085 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)March 24, 2025 | marketbeat.comSemanteon Capital Management LP Acquires 48,084 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)March 22, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by Charles Schwab Investment Management Inc.March 22, 2025 | marketbeat.comTravere Therapeutics, Inc.: Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI (sparsentan) for the Treatment of FSGSMarch 17, 2025 | finanznachrichten.deTravere Therapeutics submits sNDA to FDA for approval of FILSPARI in FSGSMarch 17, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTVTX, LEGN, TGTX, and SRPT Company DescriptionsLegend Biotech NASDAQ:LEGN$32.01 -0.87 (-2.65%) Closing price 04:00 PM EasternExtended Trading$32.02 +0.01 (+0.03%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Sarepta Therapeutics NASDAQ:SRPT$54.43 -4.18 (-7.13%) Closing price 04:00 PM EasternExtended Trading$54.60 +0.16 (+0.30%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.TG Therapeutics NASDAQ:TGTX$37.35 -1.99 (-5.06%) Closing price 04:00 PM EasternExtended Trading$37.09 -0.26 (-0.70%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.Travere Therapeutics NASDAQ:TVTX$14.99 -1.57 (-9.48%) Closing price 04:00 PM EasternExtended Trading$15.02 +0.03 (+0.20%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
